Glucagon-like Peptide 1 (GLP-1)-expressing neurons in the hindbrain send robust projections to the paraventricular nucleus of the hypothalamus (PVN), which is involved in the regulation of food intake. Here, we describe that stimulation of GLP-1 afferent fibers within the PVN is sufficient to suppress food intake independent of glutamate release. We also show that GLP-1 receptor (GLP-1R) activation augments excitatory synaptic strength in PVN corticotropinreleasing hormone (CRH) neurons, with GLP-1R activation promoting a protein kinase A (PKA)-dependent signaling cascade leading to phosphorylation of serine S845 on GluA1 AMPA receptors and their trafficking to the plasma membrane. Finally, we show that postnatal depletion of GLP-1R in the PVN increases food intake and causes obesity. This study provides a comprehensive multi-level (circuit, synaptic, and molecular) explanation of how food intake behavior and body weight are regulated by endogenous central GLP-1.
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In Brief Liu et al. show that GLP-1 signaling in PVN suppresses food intake and may prevent obesity. The molecular mechanism underlying the GLP-1 function in the PVN is via AMPA receptor subunit-GluA1 phosphorylation and subsequent membrane trafficking in a PKA-dependent pathway.
INTRODUCTION
Glucagon-like peptide 1 (GLP-1), an incretin hormone and a post-translational cleavage product of preproglucagon encoded by the Gcg gene, is mainly produced in the L-cells of the intestine and in a subpopulation of hindbrain nucleus tractus solitarius (NTS) neurons (Holst, 2007; Larsen et al., 1997) . In the central nervous system (CNS), GLP-1R agonist administration suppresses feeding and reduces body weight (McMahon and Wellman, 1998; Mietlicki-Baase et al., 2013; Secher et al., 2014; Turton et al., 1996) , but how central endogenous GLP-1 is involved in feeding control is even less understood.
The NTS GLP-1-producing GCG neurons send robust projections to many forebrain regions, including the paraventricular nucleus of the hypothalamus (PVN) (Gaykema et al., 2017; Gu et al., 2013) . The PVN is one of several brain centers implicated in food intake behavior (Betley et al., 2013; Shor-Posner et al., 1985; Sims and Lorden, 1986) . PVN contains diverse cell types, including corticotropin-releasing hormone (CRH)-, oxytocin (Oxt)-, and arginine vasopressin (AVP)-expressing neurons, which likely contribute to feeding behavior regulation (Hotta et al., 1991; Olson et al., 1991; Sutton et al., 2014) . Moreover, PVN neurons express GLP-1R (Cork et al., 2015) , and infusion of GLP-1 into the PVN suppresses food intake (McMahon and Wellman, 1998) , while GLP-1 antagonists increase food intake (Katsurada et al., 2014) . However, a recent study suggests that ablation of GLP-1R expression in Sim-1 neurons of mice shows minimal effects on food intake (Ghosal et al., 2017) , which is inconsistent with previous pharmacological studies (Katsurada et al., 2014; McMahon and Wellman, 1998) . This is likely due to (1) the difference between endogenous GLP-1 and exogenous GLP-1 agonist function, or due to the fact that (2) since GCG neurons are also proposed to co-release glutamate (Zheng et al., 2015) , GLP-1 peptide signaling is redundant or, finally, (3) that alternate neuronal pathways can compensate for the loss of GLP-1Rs, following early developmental deletion from Sim1 neurons (Fan et al., 1996) . Thus, it is crucial to understand how endogenous GLP-1 acts on PVN neurons to regulate feeding behavior, and whether the GLP-1 signal is sufficient and necessary to control food intake.
The specific signaling cascades post-GLP-1R activation likely vary depending on how G proteins (Ga s , Ga, Ga q , and Ga i/o ) selectively couple with the GLP-1 receptor (H€ allbrink et al., 2001; Montrose-Rafizadeh et al., 1999) . For example, in the peripheral pancreatic islets, GLP-1 activates adenylate cyclases, increases cAMP levels, and activates the PKA/Epac2 pathway, increasing the influx of Ca 2+ and inhibition of Kv channels (Drucker et al., 1987; Montrose-Rafizadeh et al., 1999; Thorens, 1992; Wheeler et al., 1993) . In the hypothalamus, meanwhile, GLP-1R signaling may facilitate excitatory presynaptic release 
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Gcg-Vglut2 Gcg-Cre+DIO-eYFP (Acuna-Goycolea and van den Pol, 2004) and increase presynaptic vesicle release probability in the mesolimbic dopamine system (Mietlicki-Baase et al., 2014) . However, the intracellular signaling cascades activated by GLP-1 in the PVN have not been described.
To address these outstanding questions described above, in the present study, we use a recently generated Gcg-Cre recombinase BAC transgenic mouse line (Gaykema et al., 2017) , which provides a unique tool for specifically investigating functions of NTS GCG neurons. We address the functional and anatomical impact of the NTS-to-PVN-projecting neural pathway and show that GLP-1 signaling is sufficient to suppress feeding. By using slice physiology, we show that GLP-1R activation increases the excitatory synaptic strength to CRH neurons through an enhancement of AMPA receptor (AMPAR) subunit membrane trafficking. Furthermore, we also show that phosphorylation of amino acid S845 on the C terminus of GluA1 is involved in this process. Finally, we find that postnatal ablation of PVN GLP-1R causes an increase in food intake and body weight gain, suggesting the necessity of GLP-1R signaling in the regulation of body weight homeostasis. These data elucidate the structural and molecular basis of how endogenous GLP-1 functions in the brain to control food intake and body weight.
RESULTS

NTS-to-PVN GLP-1 Projection Targets CRH Neurons
To investigate the function of endogenously released GLP-1 in the brain, we used Gcg-Cre (GLP-1 is a post-translational cleavage product of Gcg encoded preproglucagon protein) transgenic animals that we recently generated and carefully characterized (Gaykema et al., 2017) . We first asked whether PVN neuronal activity is modulated by the activity of NTS GLP-1 producing GCG neurons. Adeno-associated viruses (AAVs) harboring DIO-hM 3 Dq-mCherry, a Cre-dependent stimulatory designer receptor exclusively activated by designer drugs (DREADDs), and Cre-dependent YFP were injected into the NTS and the PVN region respectively of Gcg:CRH-Cre double transgenic mice. Administration of the DREADD ligand clozapine-N-oxide (CNO) by intraperitoneal (i.p.) injection significantly increased c-Fos protein expression in the PVN CRH neurons (labeled by YFP, Figures 1A-1D ), suggesting that CRH neuronal activity can be driven by activation of NTS GCG neurons. Interestingly, the application of Exendin-9 (Exn9), a specific GLP-1R antagonist (Turton et al., 1996) , blocked GCG neuronal activation-induced c-Fos expression in the PVN (Figures S1A and S1B), suggesting an involvement of GLP-1R signaling in NTS-to-PVN neural pathways. However, these results do not address whether the activation of CRH neurons initiated by GLP-1 is via direct or indirect GLP-1R activation.
To address this question, we first asked whether PVN CRH neurons express GLP-1R. We took advantage of FluoresceinTrp 25 -Exendin-4 (F-Exn4), which has been shown to have a similar anorexic effect as Exn4 at the same dose (Rajan et al., 2015; Reiner et al., 2016) , and is a high-affinity ligand of GLP-1R. We incubated live hypothalamic brain slices with 100 nM F-Exn4 before fixing the tissue and performing immunohistochemistry (IHC). We found that F-Exn4 labeled live neurons can be readily identified after fixation, with most expressing CRH while some were also found to express Oxt, but none were found to express AVP ( Figures S2A, S2C , and S2E). Importantly, F-Exn4 did not bind to CRH or Oxt neurons when GLP1Rs were ablated genetically, which was achieved by crossing CRH-or Oxt-Ires-Cre mice with floxed GLP-1R (GLP-1R f/f ) mice (Sisley et al., 2014) , demonstrating the specificity of the assay ( Figures S2B and S2D ). Next, we asked whether NTS GCG neurons form direct synaptic contacts with CRH neurons. Taking advantage of Channelrhodopsin 2 (ChR2)-assisted circuit mapping (CRACM), we injected the Cre-dependent AAV-ChR2-YFP and AAV-tdTomato (N) Food intake is significantly decreased after exposure to blue light in AAV-DIO-ChR2-YFP-infected Gcg-Cre mice when compared to the control group (AAV-DIO-GFP-infected Gcg-Cre mice), and in Gcg-Vglut2 KO animals. Mice were fed with $0.5 g food overnight.
(O) Food intake is significantly increased after exposure to 530 nm light in AAV-DIO-Arch3.0-YFP-infected Gcg-Cre mice when compared to the control group expressing YFP (1.2-1.5 g food fed overnight). (P) Experimental paradigm for optogenetic stimulation of GLP-1 terminals in the PVN and chemogenetic inhibition of CRH neurons. (Q) Food intake suppression induced by 470 nm light is completely abolished by silencing CRH neurons chemogenetically (0.5 g food fed overnight). Food intake amounts were 0.5 ± 0.072 g versus 0.84 ± 0.084 g (n = 9). See also Figures S1 and S2. Data are presented as mean ± SEM, and n numbers are indicated in bars. *p < 0.05; ***p < 0.001, Student's t test (C and D); one-way ANOVA, post hoc Bonferroni test (N and O); paired Student's t test (Q).
into the NTS and PVN, respectively, of Gcg:CRH-Cre transgenic mice and then performed hypothalamic brain slice recordings ( Figure 1E ). We found many GCG (i.e., GLP-1) fibers were located in close proximity to the CRH neurons in the PVN ( Figure 1F) , and blue-light-evoked EPSCs were detected in more than half of the CRH neurons, while only 5 out of 23 non-CRH neurons responded to the GCG stimulation input (Figures 1G-1I ). Since NTS GCG neurons also express vesicular glutamate transporter Vglut2 (Zheng et al., 2015) , deletion of Vglut2 would be expected to abolish the release of glutamate in GCG neurons. We thus generated the Gcg-Vglut2 knockout (KO) using the Gcg-Cre and the floxed Vglut2 (Vglut2 f/f ) mice (Tong et al., 2007) and found that light-evoked glutamate release from the GCG nerve terminal in the PVN was abolished ( Figures 1G and 1I Figure 1J ). GFP-positive cells projecting to PVN CRH neurons were found in the NTS area and half of them were also mCherry positive, indicating expression of Gcg-Cre recombinase ( Figures 1K and 1L ). Taken together, these data suggested that NTS GLP-1-producing neurons directly project to the PVN CRH neurons, yielding neuronal excitation.
NTS-to-PVN GLP-1 Signaling Is Sufficient to Suppress Food Intake
We hypothesized that targeted activation of NTS-to-PVN projections would affect feeding behavior in mice. To address this question, we injected AAV-DIO-ChR2-YFP into the NTS region of Gcg-Cre transgenic mice, and we implanted optical fibers into the PVN region bilaterally ( Figure 1M ). Optical stimulation of GCG nerve terminals within the PVN resulted in a reduction in food intake for the duration of the stimulation in animals with restricted overnight food consumption ( Figure 1N ). This suggests that the activation of the NTS-to-PVN projections is likely sufficient to suppress acute food intake. We further confirmed our observations by bilaterally injecting CNO into the PVN of GCG neuronal-specific hM 3 Dq-expressing mice to activate the GCG nerve terminals within the PVN (Figures S1C and S1D) . Importantly, Exn9, a specific blocker for GLP-1R, completely blunted the suppressive effects observed with activation of NTS-to-PVN GCG projections ( Figure S1E ), suggesting the GLP-1R signaling within the PVN is crucial to the function of GCG neurons centrally in the regulation of feeding behavior. Conversely, using DIO-eArch3.0-EYFP expressed in NTS GCG neurons to optogenetically inhibit GCG terminals in the PVN, we observed an increased food intake in non-food-restricted Gcg-Cre animals ( Figure 1O ). Together, our data suggest that NTS-to-PVN GLP-1 neural pathway is critical for central control of food intake.
Thus far, we have shown how CRH neurons in the PVN receive synaptic inputs and are regulated by NTS GCG neurons. We therefore hypothesized that PVN CRH neurons may be involved in the GLP-1-dependent regulation of food intake. However, a previous study showed that CRH neurons might not be necessary to regulate appetite, as chemogenetic inhibition of these neurons did not affect food intake (Garfield et al., 2015) , a finding that we have confirmed (Figures S1F and S1G). However, as stimulation of PVN CRH neurons slightly but significantly suppressed food intake by i.p. injection of CNO to hM 3 Dq-infected CRH-Cre mice (Figures S1H and S1I), we then examined the necessity of CRH activation in the GLP-1-dependent regulation of food intake in the PVN. We injected AAV-DIO-ChR2 and AAV-DIO-hM 4 Di into the NTS and PVN, respectively, in Gcg:CRH-Cre double transgenic animals. Prior to blue light stimulation, CNO was i.p. delivered to block CRH neuronal activity via hM 4 Di ( Figure 1P ). We found that ChR2-evoked suppression of food intake ( Figures 1M and 1N ) was at least partly blocked by inhibiting CRH neurons chemogenetically ( Figure 1Q ). Therefore, CRH neuronal activation in the PVN by GLP-1 likely contributes to suppression of food intake.
It has been suggested that GCG neurons also release glutamate in the PVN ( Figures 1G-1I ), and it is of interest to elucidate whether glutamate release in the NTS-PVN pathway may also mediate food intake regulation. We again used the Gcg-Vglut2 KO mice, which showed normal body weight and daily energy consumption compared to control animals ( Figures S1J-S1L) . Remarkably, when we utilized photostimulation of GCG neuronal terminal within the PVN, the Gcg-Vglut2 KO animals showed the exact same pattern of feeding (suppression of food intake when compared with control animals) as Gcg-Cre animals ( Figure 1N ). This suggests that the NTS GCG-to-PVN projection is sufficient to suppress food intake and this effect is likely independent of local glutamate release.
Augmentation of Excitatory Synaptic Strength in PVN CRH Neurons by GLP-1 Signaling
To investigate the cellular mechanisms underlying the GLP-1-mediated excitation of PVN CRH neurons, we focused on elucidating the synaptic mechanism. Exnedin-4 (Exn4), a specific GLP-1R agonist (Thorens et al., 1993) , significantly increased the amplitude, but not the frequency, of both spontaneous excitatory postsynaptic currents (sEPSCs) as well as miniature EPSCs (mEPSCs) in CRH neurons (Figures 2A, 2B, 2D, and 2E; Figures S3A and S3B) . Importantly, the effect of GLP-1 on mEPSCs in PVN CRH neurons was abolished by ablation of GLP-1R in this cell type, which indicates that the activation of CRH neurons is indeed directly mediated by the GLP-1R signaling cascade (Figures 2C and 2F) . Neither amplitude nor frequency of the spontaneous inhibitory postsynaptic currents (sIPSCs) was altered by , which indicates that the excitatory tone is selectively targeted by GLP-1R signaling within the PVN.
An increase in quantal size (i.e., mEPSC amplitude) can be a result of either an increase in presynaptic vesicle content or an increase expression of postsynaptic AMPARs. Given the expression of GLP-1R in the PVN CRH neurons ( Figure S2 ), we hypothesized that a postsynaptic mechanism mediates the GLP-1 regulation on synaptic transmission. To this end, we recorded evoked EPSCs (eEPSCs) in the PVN CRH neurons by local electric stimulation in the absence or presence of Exn4. We analyzed the ratio of AMPA/NMDA receptor-mediated eEPSCs and found that it was dramatically increased after application of Exn4 ( Figures 2G and 2H ). These data provide strong evidence that GLP-1 enhances excitatory synaptic transmission postsynaptically, likely via facilitating the trafficking of AMPARs to the membrane (Citri and Malenka, 2008) . Meanwhile, no change in the paired-pulse ratio (PPR) was found in the presence of Exn4, suggesting that an increase in presynaptic release is not involved (Figures S3C and S3D ). These data further strengthen the conclusion that GLP-1 signaling in the PVN facilitates CRH neuronal excitatory inputs via postsynaptic mechanisms. Additionally, we found that the fraction of PVN Oxt neurons that responded to GLP-1 also showed a similar response to Exn4 as compared to CRH neurons ( Figures S3H-S3M ). This is consistent with the in vitro F-Exn4 binding experiment, which showed that a small portion of Oxt neurons might express GLP-1R ( Figure S2C) .
It has been shown that GluA1 subunit membrane trafficking is enhanced during the early phase of long-term synaptic potentiation, potentially forming GluA2-lacking AMPARs that demonstrate inward rectification (Takahashi et al., 2003) . Thus, the rectification index measured by the ratio of AMPAR-EPSC amplitudes recorded at +40 mV holding potential versus amplitudes recorded at À70 mV has been used as an indication of AMPAR membrane trafficking (Takahashi et al., 2003) . We recorded eEPSCs in the presence of D-APV and picrotoxin at different holding potentials with an internal solution containing 100 mM spermine and calculated the rectification index, which showed an increase in the presence of Exn4 ( Figures 2I and 2J ), suggesting that GluA2-lacking AMPARs are involved in mediating GLP-1R signaling. To substantiate this, we applied IEM1460, a specific GluA2-lacking, Ca 2+ -permeable AMPAR blocker (Gittis et al., 2011; Schlesinger et al., 2005) prior to the application of Exn4, which completely blocked the augmentation effect of Exn4 ( Figures 2K and 2L ). Taken together, we propose that the post-synaptic GLP-1R signaling in CRH neurons is likely mediated by the increased membrane trafficking of GluA1.
To further test the hypothesis that GluA1 membrane recruitment is involved in GLP-1R signaling, we sought to examine the impact of blocking GluA1 trafficking. Given that expression of the cytoplasmic termini (CT) of GluA1 has been previously shown to block trafficking of endogenous GluA1 in a dominant-negative manner (McCormack et al., 2006) , we infected PVN neurons with sindbis viruses expressing either GluA1-CT-GFP or GFP alone. GluA1-CT-GFP expressing CRH neurons did not show augmentation of mEPSC amplitudes after the application of Exn4 ( Figures 2M-2O ). Additionally, in animals with PVN overexpression of GluA1-CT-GFP, the PVN-targeted Exn4 injection-induced food intake suppression effects were blunted ( Figures 2P and 2Q) . Interestingly, the expression of GluA1-CT-GFP in PVN itself did not alter basal food intake ( Figures S4A  and S4B ).
Taken together, these comprehensive data strongly suggest that GLP-1 signaling in the PVN augments CRH neuronal excitatory synaptic strength that likely results from enhanced AMPAR membrane trafficking.
Enhanced Trafficking of AMPAR Mediates GLP-1R Signaling
If our interpretation that GLP-1R signaling facilitates AMPAR trafficking is correct, we should be able to directly examine how changes in signaling cascades downstream of GLP-1R activation affect GluA1 trafficking to the plasma membrane. To address this, we transfected GluA1 and GLP-1R into the mouse brain neuroblastoma cell line Neuro-2a (N2a). After a 15 min treatment with Exn4, a surface biotinylation-labeling assay was employed to isolate membrane proteins (Man et al., 2007) and showed that the membrane expression of GluA1 was dramatically increased by treatment with Exn4 ( Figure 3A) . Previous reports suggest that GluA1 membrane trafficking is regulated by protein phosphorylation at two sites on the intracellular carboxy terminal motif of the receptor (Roche et al., 1996) , i.e., serine 831 (S831), which is phosphorylated by CaMKII and protein kinase C, and serine 845 (S845), which is phosphorylated by PKA (Barria et al., 1997; Mammen et al., 1997; Roche et al., 1996) . We asked whether phosphorylation of GluA1 mediates the actions of GLP-1, with the rationale being that GLP-1R activation should increase intracellular cAMP (Drucker et al., 1987) and PKA activation. Unfortunately, the phosphorylation of GluA1 was too low to detect either in vivo or in vitro in hypothalamic neurons (data not shown). We again used the N2a cell line and enriched GluA1 by first immunoprecipitating (IP) GluA1 utilizing a pH-sensitive form of GFP (super ecliptic pHluorin [SEP]) tagging and performed western blotting using phosphorylation site-specific antibodies. Remarkably, we found that phosphorylation of S845, but not S831, was drastically increased after Exn4 treatment ( Figure 3B ). On the other hand, the phospho-deficient S845A GluA1 mutant failed to respond to GLP-1R activation ( Figures 3A and 3B ). These data strongly suggest that GluA1 S845 is likely a specific target of GLP-1R signaling in the brain.
To further address this hypothesis, we took advantage of a GluA1 S845A knockin mouse line (Lee et al., 2003) and tested the effects of GLP-1R signaling on synaptic transmission. Interestingly, Exn4-induced upregulation of mEPSC amplitude on CRH neurons was no longer detected in GluA1 S845A mutant mice ( Figures 3C and 3D) . Although S845A mutant mice show normal daily food intake ( Figure 3E ), the PVN administration of Exn4-induced suppression of food intake was completely blunted ( Figure 3F ), suggesting that S845 phosphorylation of GluA1 is crucial in mediating the effects of GLP-1R on PVN neuronal activation.
To explore the hypothesis that PKA signaling mediates the actions of GLP-1 on AMPAR phosphorylation, we observed that the application of H-89, a PKA blocker, blocked Exn4-induced GluA1 S845 phosphorylation and surface GluA1 accumulation ( Figures 3G and 3H) . However, in addition to the effects on PKA, it is also possible that GLP-1R signaling affects the activity of exchange proteins activated by cAMP (EPAC) (Mangmool et al., 2015) to facilitate GluA1 trafficking. Contrary to this hypothesis, unlike the effects of H-89, application of ESI-09, an EPAC inhibitor, did not block either Exn4-induced membrane GluA1 trafficking or GluA1 phosphorylation ( Figures S4C and  S4D) . Thus, we propose that GLP-1-mediated GluA1 membrane trafficking is PKA but not EPAC dependent. Finally, to address the functional significance of our findings that a GLP-1-PKA pathway is likely mediating AMPAR trafficking, we tested whether a blockade of the PKA pathway in the PVN would blunt suppression of food intake elicited by GLP-1R activation. We found that administration of H-89 directly to the PVN was sufficient to block the suppressive effects of Exn4 in the PVN on food intake ( Figures 3I and 3J) , while H-89 itself did not affect food intake ( Figures S4E and S4F) , which may be due to H-89 blockade of Exn4-induced augmentation of mEPSC amplitude in PVN CRH neurons ( Figures 3K and 3L) .
Collectively, these data provide strong evidence that GLP-1 mediates synaptic plasticity by specifically increasing the S845 site phosphorylation of GluA1 via the PKA pathway, promoting GluA1 membrane trafficking and augmenting excitatory neurotransmission in the PVN to suppress food intake.
Impaired GLP-1R Signaling in the PVN Causes Obesity As described previously, week-long stimulation of NTS GCG neurons by hM 3 Dq did not affect body weight change in lean mice. Rather, it did significantly decrease the body weight of the obese mice that were fed by high-fat food for 5 months (Gaykema et al., 2017) . Chemogenetic inhibition of NTS GCG neurons for 1 week showed a slight increase in the daily food intake but with no obvious body weight gain when compared to control group ( Figures S4L-S4N ). Given the profound effects of GLP-1 signaling in the PVN on food intake ( Figures 1N and 1O) , we Data are presented as mean ± SEM or absolute values, **p < 0.01, n numbers are indicated in bars or as indicated. K-S tests and paired t tests were employed for D and L cumulative curve and inserted dot plots; one-way ANOVA was used for (E), (F), and (J). See also Figure S4 .
asked whether blockade of GLP-1R signaling in the PVN affects energy metabolism and body weight gain. However, a recent study showed that conditional knockout of GLP-1R in Sim-1 neurons in mice had no impact on food intake and body weight (Ghosal et al., 2017) . We suspected that, in this instance, a developmental compensatory effect could account for the lack of a feeding phenotype, as Sim-1-driven Cre expression likely occurs during embryogenesis (Fan et al., 1996) . Therefore, we injected AAV-Cre in the PVN of juvenile GLP-1R f/f animal at 5-6 weeks of age, which resulted in a significant decrease of GLP1-R expression in PVN, but not in the dorsal medial hypothalamus (DMH) or the arcuate nucleus (ARC) (Figures S4G-S4J ). Remarkably, in the AAV-Cre-injected animals, i.e., PVN neuronal GLP-1R knockout mice, we observed a significant gain in body weight when compared to controls (injected with AAV-DCre, expressing an inactive Cre-recombinase) in GLP-1R f/f mice but not in WT animals (Figures 4A and 4B ; Figure S4K ). The Cre-injected mice also exhibited an elevation in daily food intake ( Figure 4C ). With respect to metabolic rate, no difference in O 2 consumption ( Figure 4D ), CO 2 elimination ( Figure 4E ) or respiration exchange ratio ( Figure 4F ) was observed, suggesting that energy expenditure and the selection of fuel substrates were not altered after depletion of GLP-1R in the PVN ( Figure 4I ). While movement in the x axis was unaffected, a significant decrease of z axis activity when compared to control animals ( Figures 4G and 4H ) was observed. Interestingly, GLP-1R depletion also produced an increase in fasting glucose levels and impaired insulin sensitivity ( Figures 4J and 4K) , indicative of insulin resistance. These data suggest that PVN GLP-1R signaling is necessary to maintain energy homeostasis in adult mice.
DISCUSSION
In this study, we unraveled the cellular mechanism underlying a specific neuronal circuit, involving NTS GCG neuronal projections to PVN neurons, which are involved in regulating feeding behavior. Stimulation of the NTS-to-PVN GCG neuronal projection is sufficient to mediate a change in food intake, and GLP-1R expression in the PVN is necessary for regulating food intake as well as maintaining normal body weight. GLP-1 in the PVN likely functions via the following pathway ( Figure 5 ): (1) GLP-1R signaling activates the PKA signaling pathway, which causes (2) phosphorylation of GluA1 S845, leading to (3) enhancement of GluA1 membrane trafficking, and finally (4) augmentation of postsynaptic excitatory synaptic transmission.
NTS-to-PVN Projecting GLP-1 Neurons Suppress Food Intake via Activation of GLP-1Rs
It was shown that infusion of Exn4 within the PVN suppresses food intake while Exn9 increases it (Katsurada et al., 2014; McMahon and Wellman, 1998) , which suggests that GLP-1R signaling in the PVN is sufficient to regulate food intake. In contrast, however, specific ablation of GLP-1R from Sim-1 neurons in PVN does not affect food intake and body weight gain, which suggests GLP-1R signaling is not necessary to control feeding behavior (Ghosal et al., 2017) . To address this disparity in the data, we used optogenetics to manipulate the activity of the GCG neuron in the presence or absence of glutamate corelease using genetic tools and found that secretion of the GLP-1 peptide independent of glutamate release is sufficient to regulate food intake. Interestingly, the food intake suppression induced by 1 hr activation of the GCG nerve terminals was shown to last at least 1 more hour after the completion of photostimulation, which might be due to a delayed recovery in synaptic strength modifications after GLP-1R activation or a prolonged circuit activation downstream of the PVN neurons. Moreover, we also addressed the necessity of the GLP-1R signaling by using loss-of-function experiments, i.e., optogenetic inhibition as well as PVN GLP-1R KO with both manipulations causing overeating behaviors in animals.
Specific neuronal subtypes within the PVN are thought to drive PVN-dependent anorexia (Darambazar et al., 2015; Otgon-Uul et al., 2016; Santoso et al., 2015; Sedbazar et al., 2014) . We identified a large proportion of CRH-expressing PVN neurons that were activated (indicated by the expression of the activity marker c-Fos) following NTS GCG neuronal stimulation. We further substantiated the hypothesis that PVN CRH neurons are a major target of GLP-1 signaling with the following evidence: (1) over one-third of CRH neurons can bind F-Exn4 in vitro, suggesting the presence of GLP-1R expression in those neurons; (2) CRACM experiments show that over 50% of CRH neurons receive direct projections from the NTS GCG neurons; (3) the PVN. Thus, we suggest CRH neuron activation might contribute to the regulation of food intake behavior induced by endogenous GLP-1. Although CRH is the central player in the hypothalamic-pituitary-adrenal (HPA) axis, previous data show that stimulation of central GCG neuronal activity by hM 3 Dq does not affect plasma corticosterone levels, as well as anxiety related behavior (Gaykema et al., 2017) . Therefore, CRH-mediated GLP-1 satiety effect may not be due to the secondary effect of HPA axis activation.
In addition to CRH neurons in the PVN, other neuronal subtypes, i.e., Sim-1-expressing neurons, may also mediate the GLP-1 effect since inhibiting Sim-1 neuronal activity causes a massive increase in feeding (Garfield et al., 2015) . Moreover, MC4R-expressing neurons, a subset of Sim-1 neurons, also play a pivotal role in food intake (Atasoy et al., 2012) . However, inhibition of MC4R neurons alone appeared to cause less increase in food intake when compared to the inhibition of Sim-1 neurons (Atasoy et al., 2012; Garfield et al., 2015) , which suggests other subsets of PVN MC4R-negative Sim-1 neurons contribute to food intake regulation. Thus, further work will be required to determine the regulatory functions of GLP-1 in the brain and how this peptide can synergize with these and other modulatory systems.
GLP-1R Signaling Regulates CRH Activity by Recruitment of Membrane AMPARs
GLP-1 has profound effects on synaptic transmission (for review, see Liu and Pang, 2016) ; however, the intracellular signaling cascades and pre-or postsynaptic site of action appear to be dependent on brain region and cell type (Acuna-Goycolea and van den Pol, 2004; Korol et al., 2015; Wang et al., 2015) . In the current study, we showed that GLP-1R activation by Exn4 facilitates excitatory input in the PVN CRH neurons, in line with the anorexigenic role of this cell type (Hotta et al., 1991; Katsurada et al., 2014) . We further provided compelling evidence that a postsynaptic mechanism is involved, most likely via the facilitation of AMPAR trafficking. Initially, we showed that quantal size of EPSCs and the ratio of EPSCs mediated by AMPAR and NMDAR in PVN CRH neurons were both increased; subsequently, we determined that the rectification index of EPSCs, a measure of detecting newly formed AMPAR-lacking GluA2, was increased. In addition, IEM1460, a specific GluA2-lacking AMPAR blocker (Gittis et al., 2011; Schlesinger et al., 2005) , blunted the effects of Exn4 at synapses, and the blockade of AMPAR trafficking in the PVN blunted both the food intake suppression effects as well as the facilitation of EPSCs mediated by GLP-1R activation. We conclude that GLP-1R activation induces GluA1 trafficking that facilitates excitatory synaptic drive and increases the excitability of CRH neurons, which may contribute to the suppression of food intake. Although GCG neurons that terminate in the PVN co-release glutamate, glutamate release is not necessary or sufficient for controlling feeding behavior in this neural pathway. The inputs and outputs of the CRH neurons have not been completely characterized and further studies will be needed to determine which afferents mediate the observed modulatory effects of GLP-1 on EPSCs in the PVN. Nevertheless, a recent paper suggests a small population of glutamatergic neurons in ARC that project to PVN MC 4 R neurons rapidly affect the suppression of food intake (Fenselau et al., 2017) . Considering that the MC 4 R intracellular signaling pathway is the same as that initiated by GLP-1R activation (cAMP-PKA), it is possible that GLP-1 strengthens the excitatory input from ARC glutamate neurons and regulates food intake in a manner similar to that of a-MSH, which acts postsynaptically. Our retrograde tracing experiment suggests that PVN CRH neurons receive inputs from DMH, suprachiasmatic nucleus, central amygdala, as well as hippocampus (data not shown), areas that could also possibly provide the source of the excitatory input.
With respect to AMPAR trafficking, S831 and S845 phosphorylation in the GluA1 C terminus has been suggested to be crucial for the recruitment of receptor subunits to the membrane (Barria et al., 1997; Mammen et al., 1997; Roche et al., 1996) . While S831 is phosphorylated by PKC and CaMKII, the phosphorylation of which potentiates the single-channel conductance of GluA1-containing AMPARs (Derkach et al., 1999; Derkach, 2003) , S845 is phosphorylated by PKA, which increases the open probability (Banke et al., 2000) and surface expression of the receptors (Ehlers, 2000) . In the present study, we identified that phosphorylation of S845, but not S831 occurs in response to GLP-1R activation, indicating an involvement of the PKA pathway. Specifically, blocking the PKA pathway inhibits S845 phosphorylation induced by GLP-1 signaling, while the S845A mutation blocked Exn4-induced GluA1 membrane insertion in vitro. Collectively, these data suggest that S845 of GluA1 is an important target for GLP-1 signaling. To further support this conclusion, we tested the effects of GLP-1 signaling in a GluA1 S845A knockin animal model. Strikingly, Exn4-induced suppression of food intake within the PVN was completely blunted in mutant mice and the augmentation of EPSCs mediated by GLP-1R signaling was abolished. These data strongly support our hypothesis that GLP-1R signaling regulates CRH neuron activity by recruitment of membrane AMPARs, likely via PKA phosphorylation of S845 in GluA1.
Loss of Function of GLP-1R Induces Obesity
In addition to investigating the molecular underpinnings of GLP-1R signaling in the PVN, we also tested the physiological relevance of GLP-1R in regulating body weight and metabolic homeostasis. While deletion of GLP-1R in the PVN increased food intake, no effect on metabolic rate was observed. Moreover, the long-term depletion of GLP-1R signaling within the PVN caused a 30% increase in body weight over a 6-week period, with mice developing elevated fasted glucose levels and impaired insulin sensitivity. Our work reveals a striking contrast between the mechanism of action of endogenous GLP-1 and that of the systemically administered GLP-1R agonist liraglutide in mediating changes in body weight. While peripheral agonist administration does not require the PVN GLP-1R expression to produce body weight changes (Secher et al., 2014) , we show that endogenous GLP-1 signaling does. This discrepancy may be due to the fact that significantly more peripherally administered liraglutide appears to target ARC rather than the PVN (Secher et al., 2014) , whereas innervation of both structures by GCG neurons is similar in mice (Gaykema et al., 2017; Llewellyn-Smith et al., 2011) . Although differences between mouse and rat physiology may also explain the data, prior work in the rat has also failed to show an effect of GLP-1 injection in the ARC on feeding behavior (Sandoval et al., 2008) . Future work will therefore be required to determine whether and to what degree ARC GLP-1R signaling in the mouse mediates an effect of endogenous GLP-1 on body weight homeostasis.
Previous pharmacological studies (i.e., infusion of agonist) suggested that the hypothalamic GLP-1 signal may play a role in the maintenance of glucose homeostasis (Sandoval et al., 2008) ; however, the ablation of GLP-1R in PVN does not affect glucose metabolism (Burmeister et al., 2017) . And a recent report shows that stimulation of endogenous GLP-1 does not affect performance in the glucose and insulin tolerance tests either (Gaykema et al., 2017) . Thus, the impaired glucose tolerance and insulin sensitivity that we observed in our PVN GLP-1R KO adult mouse model is likely due to the secondary effect of obesity.
While our postnatal viral-mediated deletion of GLP-1R from the PVN perturbed body weight homeostasis, the CRH-or Oxt-neuronal-specific GLP-1R KO, surprisingly, did not (data not shown). This may have occurred for several reasons: (1) compensatory pathways may have developed to rescue impaired signaling of GLP-1R within the PVN during development, as GLP-1R was deleted during an early developmental stage, an effect that was likely similar to prior work that showed how Sim1-Cre-mediated GLP-1R knockout mice had normal food intake and body weight gain (Ghosal et al., 2017) ; (2) GLP-1R was not deleted from both CRH and Oxt neurons simultaneously, which may have been required to observe the body weight phenotype; and (3) GLP-1R signaling in CRH neurons of other brain regions (e.g., central amygdala or brain stem) may exert an opposite role in the regulation of body weight homeostasis when compared to those in the PVN. Nevertheless, based on the viral-mediated reduction of GLP-1R expression in the PVN leading to obesity and defects in glucose tolerance, we conclude that GLP-1R is necessary in mediating NTS-to-PVN signaling in central control of metabolic homeostasis.
In summary, this study unravels a previously unidentified molecular cascade, describing the mechanism by which NTSderived GLP-1 modulates neuronal activity and food intake behavior, while also showing that defective PVN GLP-1 signaling causes obesity ( Figure 5 ). This work provides a framework for studying the mechanism of action of other GPCR-coupled receptors in the brain.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS Mice
All procedures involving mice were approved by the Rutgers Robert Wood Johnson Medical School Institutional Animal Care and Use Committee (IACUC). All the animals used in this study were 6-8 week old males unless otherwise stated. The animals are bred in the facility at $22 C and 35%-55% humidity. The Gcg-Cre transgene was created by insertion of Cre-recombinase into the Gcg gene locus of BAC RP23-242F22 at the ATG start codon. The BAC transgene was then injected into pronuclei from C57BL/6j animals to create Gcg-Cre transgenic animals (Gaykema et al., 2017) . The CRH-Ires-Cre (Taniguchi et al., 2011) and oxytocin (Oxt)-Ires-Cre mice (Wu et al., 2012) were purchased from Jackson Laboratories (Stock#: 012704 and 024234, respectively). GLP-1R f/f mice were described previously (Sisley et al., 2014) . The Vglut2 f/f mice (Tong et al., 2007) were purchased from Jackson Laboratories (Stock#:012898). GluA1 S845A mutant mice were generously provided by Dr. Richard Huganir at the Johns Hopkins University (Lee et al., 2003) . Wild-type mice C57BL/6 were purchased from Jackson Laboratories. In all cases, mice were randomized according to body weight to each experimental group. The investigator was blinded to the treatment groups except Figures 1Q, 2Q , 3F, and 3J, Figure S1G . The sample size required was estimated to be n = 7-10 per group on the basis of previous studies examining the effects of GLP-1 on feeding behavior .
Cell Culture
Neuroblastoma cell line, Neuro-2a (N2a) cells (provided by Dr. Huaye Zhang as a gift, Rutgers University, original source from ATCC and was authenticated by ATCC), were cultured in 10 cm diameter dishes using regular DMEM medium containing 10% heat inactivated fetal bovine serum (FBS, Atlanta Biologics). Cells are kept in incubator: 37 C, 4%-10% CO2. Cells are expected in 70%-90% confluent for transfection, 6mg GLP-1R (addgene) and 6mg GluA1 (addgene) plasmid are transfected by Lipofectamine 3000 (Life technologies). Cells are harvest 48 hr post-transfection.
METHOD DETAILS
Virus infection AAV virus
The AAV-viruses used in this study include: AAV-hSyn-DIO-hM 3 Dq-mCherry, AAV-hSyn-DIO-hM 4 Dq-mCherry, AAV-hSyn-DIOmCherry, AAV-CAG-DIO-tdtomato, AAV-EF1a-DIO-ChR2-YFP, AAV-EF1a-DIO-eArch3.0-YFP or AAV-EF1a-DIO-GFP (purchased from the University of North Carolina Gene Therapy Center); AAV-Cre-GFP and AAV-DCre-GFP were generated in house or obtained from Dr. Wei Xu at UT Southwestern Medical Center. The ChR2-YFP encodes a membrane-bound fusion protein, allowing visualization of both the cell bodies and axons of Cre-expressing neurons for morphologic analyses. Viral-mediated protein expression was allowed for a period of 14 days prior to experimental manipulation. Injection sites were confirmed by cutting brain sections and inspecting them under a stereoscope or microscope in all animals reported in this study. 0.6-1 mL virus was used for the injection of the Cre-dependent expression AAV virus. Three weeks post-AAV transduction, we injected SADDG -EGFP into the same area to infect CRH neurons. One week prior to SADDG -EGFP injection, the Cre-dependent mCherry (AAV-DIO-mCherry) virus was injected into the NTS to label GLP-1 expressing neurons.
Expression of GluR-C termini (CT) by Sindbis virus
Sindbis virus was transfected into PVN neurons, expressing the GFP-tagged cytoplasmic termini of GluA1. GluA1-CT-GFP selectively blocks the trafficking of endogenous GluA1-containing AMPARs as described before (Kielland et al., 2009 ). The coordinates used for Sindbis virus injection (0.2 mL) in the PVN were: AP À0.94; L: ± 0.25; V: 4.75. The in vivo behavior testing and in vitro recording were performed three days after injection.
PVN cannula placement
The bilateral guide cannulas (Plastics one, C2002DCS-5) or optic fibers (ThorLabs, 200 mm diameter core) (Sparta et al., 2011) were implanted into the PVN and fixed to the skull with cement and three screws. The coordinates used for the PVN were: AP: À0.94; L: ± 0.25; V: 4.6 and AP: À0.94; L: ± 0.25; V: 4.5 for the guide cannulas and optic fibers, respectively. After surgery, mice were housed individually and were allowed to recover for 2 weeks before experimentation. The cannula/optic fiber location was checked after sacrifice of animals; data were collected only from animals with proper placement.
Channelrhodopsin (ChR2)-assisted circuit mapping Gcg:CRH-Cre animals were injected by AAV-hSyn-DIO-ChR2-YFP and AAV-hSyn-DIO-tdTomato into NTS and PVN, respectively. Two weeks post-surgery, mice were deeply anesthetized with Euthasol. Coronal hypothalamic slices (300 mm) were prepared and whole cell patch clamp recordings were performed at 30 C in ACSF containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 2.5 Glucose, 22.5 Sucrose, 2.5 CaCl 2 , 1.2 MgCl 2 . Photostimulation-evoked EPSCs were recorded in the whole cell voltage clamp mode, with membrane potential clamped at À70mV. Photostimulation evoked EPSCs were recorded in the presence of picrotoxin (100 mM) to block inhibitory postsynaptic currents. 20 mM CNQX was used to confirm that the response was indeed from EPSCs. All recordings were made using a multiclamp 700B amplifier, and data were filtered at 2 kHz and digitized at 10 kHz. To photostimulate ChR2-positive fibers, a LED light source was used to generate 470nm blue light, which was focused on to the back aperture of the microscope objective, producing a wide-field exposure of the PVN area. The photostimulation-evoked EPSC detection protocol was described before (Krashes et al., 2014) and involved four blue light laser pulses administered 1 s apart during the first 4 s of an 8 s sweep, repeated for a total of 16 sweeps.
Immunohistochemistry (IHC)
Mice were deeply anesthetized with Euthasol and transcardially perfused with 4% PFA in PBS, pH 7.4. Coronal brain slices (45 mm) were prepared and a standard IHC protocol was followed. The primary antibodies used were anti-c-Fos (1:1000, Santa Cruz, SC-271243); anti-AVP (1:1000, Millipore, ab 1565); anti-OXT (1:1000, Millipore, ab 911). AlexaFluor secondary antibodies (633-goat anti-mouse, 1:1000; 546-goat anti-rabbit, 1:1000, Life Technologies, A21052 and A11035 respectively) were used to visualize the signal and images were acquired by confocal microscopy (Zeiss, LSM700).
Live cell labeling with F-Exn4
The CRH-Ires-Cre mice were injected with AAV-DIO-mCherry. Two weeks after, mice were sacrificed and coronal hypothalamic slices (300 mm) were incubated at 30 C for 20 min in oxygenated artificial cerebrospinal fluid (ACSF) containing (in mM): 125 NaCl, 2.5 KCl, 1.25 NaH 2 PO 4 , 25 NaHCO 3 , 2.5 Glucose, 22.5 Sucrose, 2.5 CaCl 2 , 1.2 MgCl 2 . The slices were incubated with 100 nM Fluorescein-Trp 25 -Exendin-4 (F-Exn4, Anaspec, cat # AS-63899) in ACSF at room temperature for 15 min. 4% PFA was used to fix the tissue directly after removing ACSF. The slices were washed well with PBS prior to immunostaining. The primary antibodies used were: anti-OXT (1:1000, Millipore, ab911); anti-AVP (1:1000, Millipore, ab1565). The secondary antibodies used were: Alex-546-goat anti-rabbit (1:1000, Life Technologies, A11035) and Alex-633-goat anti-mouse (1:1000, Life Technologies, A21052). The cell numbers showing in figure S2 are averaged from 4 animals.
Behavior experiments
Optogenetic manipulation of GLP-1 fibers Optical fibers (200 mm diameter core), NA 0.37 (Thorlabs) were coupled to a fiber optic rotary joint (Prizmatix) and the LED generator (470 nm for stimulation, Prizmatix UHP-T-470-LA, 530nm for inhibition, Thorlabs M530F2). A terminal fiber attached to the rotary joint was coupled to a 1.25 OD zirconium ferrule and a mating sleeve which allowed delivery of light to the brain. For in vivo photo-stimulation experiments, 5 ms pulses 470nm blue light were given as 10 pulses/s every 4 s for 1 hr. For the in vivo photo-inhibition experiments, 10min constant 530nm green light intervals with 5 min breaks between stimulation were administered for 1hr. For the stimulation experiment, animals were provided only 0.5g food overnight. For the inhibition experiment, animals were provided 1.2-1.5g food overnight. All the mice were trained for 4 days to acclimate to the feeding schedule. Food intake was measured at 0.5 hr, 1 hr, 2 hr, and 5 hr. Excitatory/inhibitory DREADDs For local stimulation of GLP-1 fibers in the PVN, Gcg-Cre mice were injected with hM 3 Dq AAV virus in the NTS. After 2 weeks recovery, 5 mM (200 nL) of CNO (Tocris) was used for intracranial injection into the PVN through a guide cannula. Food intake was monitored 30min post-injection. To block GLP-1 receptor activation in the PVN, Exendin 9-39 (Exn9) was injected into the PVN through the guide cannula 10 min prior to CNO injection. For inhibition of NTS GLP-1 neurons, hM 4 Di AAV virus was injected 2 weeks prior to CNO injection. 0.3 mg/kg CNO was given by i.p. injection every day at 6:00pm for one week. Food intake and body weight were monitored every day. To stimulate endogenous CRH neurons, CRH-Cre mice were injected with hM 3 Dq AAV virus in PVN. After 2 weeks recovery, 0.3mg/kg CNO was given by i.p. injection. Food intake was monitored 30 min later. Exciting GLP-1 and inhibiting CRH We injected AAV-DIO-ChR2 and AAV-DIO-hM 4 Di into NTS and PVN, respectively, in Gcg:CRH-Cre transgenic animals. After 2 weeks recovery, the mice were trained for an additional four days to consume 0.5g of food overnight and received an i.p. injection of phosphatebuffered saline (PBS, 100 mL). From the fifth to eighth day, the animals were treated with: PBS only, CNO only (0.3mg/kg), PBS (30 min prior) + blue light, CNO (30 min prior) + blue light respectively. Food intake was monitored at t = 30 min, 1 hr and 2 hr from the fifth day. PKA-GluA1 pathway effect on food intake To study the GluA1 mediated GLP-1 anorexigenic effect, we randomly divided the mice into three groups: control + vehicle (Veh, sindbis virus-GFP + intra-PVN injection of saline); control + Exn4 (sindbis virus-GFP + intra-PVN injection of 0.1 mg/200 nL Exn4); and GluA1-CT + Exn4 (sindbis virus-GluA1-CT-GFP + intra-PVN injection of 0.1 mg/200 nL Exn4). Food was measured at t = 0, 30, 60, and 120 min after injection.
To study how the phosphorylation of GluA1 effected food intake, we injected either vehicle (200nl saline) or Exn4 (0.1 mg/200 nL) into the PVN of control (WT mice) and mutant (GluA1 S845A Knockin) mice using a guide cannula.
To block the PKA pathway in the PVN, 500 nL (5 mM) of the PKA inhibitor H-89 was locally injected through the guide cannula 10min prior to delivery of Exn4 into PVN of WT animals. Depletion of GLP-1R in PVN Body weight was monitored every week post-surgery (week 0). On week three, animals were separated into individual cages to adapt to their surroundings for one day. Food intake was measured on the third day. During week 6, all the animals were placed into metabolic cages (Columbus Instruments, Comprehensive Lab Animal Monitoring System (CLAMS), OH, USA) to adapt to their surroundings 12 hr before measurement. All metabolic data were collected in night phase. For the insulin tolerance test during week 6, animals
